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The Middle-East Respiratory Syndrome coronavirus (MERS-CoV) causes severe acute pneumonia and
renal failure. The MERS-CoV papain-like protease (PLpro) is a potential target for the development of anti-
viral drugs. To facilitate these efforts, we determined the three-dimensional structure of the enzyme by
X-ray crystallography. The molecule consists of a ubiquitin-like domain and a catalytic core domain. The
catalytic domain displays an extended right-hand fold with a zinc ribbon and embraces a solvent-
exposed substrate-binding region. The overall structure of the MERS-CoV PLpro is similar to that of the
corresponding SARS-CoV enzyme, but the architecture of the oxyanion hole and of the S3 as well as
the S5 speciﬁcity sites differ from the latter. These differences are the likely reason for reduced in vitro
peptide hydrolysis and deubiquitinating activities of the MERS-CoV PLpro, compared to the homologous
enzyme from the SARS coronavirus. Introduction of a side-chain capable of oxyanion stabilization
through the Leu106Trp mutation greatly enhances the in vitro catalytic activity of the MERS-CoV PLpro.
The unique features observed in the crystal structure of the MERS-CoV PLpro should allow the design
of antivirals that would not interfere with host ubiquitin-speciﬁc proteases.
 2014 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction
Ten years after the outbreak of severe acute respiratory syn-
drome (SARS) of 2002/2003 (Hilgenfeld and Peiris, 2013), another
highly pathogenic coronavirus, Middle-East Respiratory Syndrome
coronavirus (MERS-CoV), has been recognized to infect humans
(Zaki et al., 2012; de Groot et al., 2013). Accumulating evidence
suggests camels to act as a zoonotic source of the virus (Reusken
et al., 2013; Haagmans et al., 2014; Meyer et al., 2013). Limited
human-to-human transmission of the virus has been described
(Assiri et al., 2013). As of June 11, 2014, 683 cases of MERS have
been reported, with 204 deaths (http://www.who.int). The clinical
symptoms of MERS include severe pneumonia and sometimes
acute renal failure (Eckerle et al., 2013). However, the majority of
MERS patients had/has comorbidities, such as diabetes, lung dis-
ease, or chronic renal disease (Perlman, 2013).SARS-CoV and MERS-CoV belong to the genus Betacoronavirus
but pertain to highly distinct phylogenetic clades termed b and c,
respectively (de Groot et al., 2013). In case of SARS-CoV, the best-
characterized potential antiviral drug targets are the two viral pro-
teases, the main protease (Mpro, also called 3C-like protease, 3CLpro)
(Hilgenfeld and Peiris, 2013; Anand et al., 2003; Yang et al., 2003,
2005; Xu et al., 2005; Lu et al., 2006; Verschueren et al., 2008; Zhu
et al., 2011; Kilianski et al., 2013) and the papain-like protease
(PLpro) (Hilgenfeld and Peiris, 2013; Kilianski et al., 2013; Barretto
et al., 2005; Ratia et al., 2006, 2008; Baez-Santos et al., 2014). The
latter enzyme exists in all coronaviruses (Woo et al., 2010) and
has been shown to be responsible for releasing non-structural pro-
teins (Nsp) 1, 2, and 3 from the N-terminal part of polyproteins 1a
and 1ab. The three cleavage sites contain the sequence motif
LXGG;XX. In addition, the SARS-CoV PLpro has been shown to have
deubiquitinating and interferon antagonism activities, thereby
interfering with the host innate immune response (Barretto et al.,
2005; Lindner et al., 2005; Devaraj et al., 2007; Frieman et al.,
2009). Speciﬁcally, it can prevent the activation of IRF3 (inter-
feron-regulatory factor 3) and antagonize the NF-jB (nuclear factor
j-light-chain-enhancer of activated B cells) pathway, but the
Table 1
Data collection and reﬁnement statistics.
MERS-CoV PLpro
Data collection statistics
Space group C2
Unit-cell dimensions (Å, ) a = 100.89, b = 47.67, c = 88.43
b = 122.35
Wavelength (Å) 0.98
Vm (Å3/Da) 2.53
Solvent content (%) 51.34
Resolution range (Å) 42.62–2.50 (2.64–2.50)
Number of unique reﬂections 12337
Rmerge 0.059 (0.472)
Rpim
1 0.025 (0.194)
Completeness (%) 99.0 (98.3)
Mean I/r (I) 19.2 (3.9)
Multiplicity 6.6 (6.8)
Reﬁnement statistics
Rcryst (%)2 18.7 (23.6)
Rfree (%)2 23.4 (30.3)
No. of atoms
Protein 2462
Ligand/ion 1
Water 94
Clashscore3 2
r.m.s.deviation in bond lengths (Å) 0.01
r.m.s.deviation in bond angles () 1.13
Average B-factor for all atoms (Å2) 61
Ramachandran plot
Residues in favored regions (%) 96.8
Residues in additionally allowed regions (%) 3.2
Residues in outlier regions (%) 0
1 Rpim (Weiss and Hilgenfeld, 1997).
2 Rcryst =
P
hkl|Fo(hkl)  Fc(hkl)|/
P
hkl Fo(hkl). Rfree was calculated for a test set of
reﬂections (4.9%) omitted from the reﬁnement.
3 Clashscore is deﬁned as the number of clashes calculated for the model per
1000 atoms (including hydrogens) of the model. Hydrogens were added by Mol-
Probity (Chen et al., 2010).
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MERS-CoV PLpro has been reported to also have proteolytic, deubiq-
uitinating, and deISG15ylating activities in HEK293T cells (Yang
et al., 2013; Mielech et al., 2014) (ISG15 = interferon-stimulated
gene 15); it therefore also acts as an interferon antagonist through
blocking the IRF3 pathway. Interestingly, these reports differ in
their ﬁnding that the interferon-antagonizing activity of the
MERS-CoV PLpro is either independent of (Yang et al., 2013) or
dependent on (Mielech et al., 2014) its proteolytic activity.
In spite of the accumulating knowledge on the essential roles of
the coronavirus PLpro in virus replication and evasion of the host-
cell innate immune response (Devaraj et al., 2007; Frieman et al.,
2009; Yang et al., 2013; Mielech et al., 2014; Lindner et al., 2007;
Clementz et al., 2010), the three-dimensional structures of only
two of these enzymes have been reported so far, i.e., that of the
PLpro from SARS-CoV (Ratia et al., 2006) and that of the PL1pro from
Transmissible Gastroenteritis Virus (TGEV) (Wojdyla et al., 2010).
Here we present the crystal structure of the MERS-CoV PLpro at
2.50 Å resolution, in order to unravel the structural basis of the
activities of the enzyme and facilitate structure-based drug design
efforts. In addition, we report the in vitro hydrolytic activities of the
enzyme towards two synthetic peptide substrates and a ﬂuoro-
genic ubiquitin derivative.
2. Materials and methods
2.1. Recombinant production of MERS-CoV papain-like protease (PLpro)
The PLpro of MERS-CoV (strain 2c EMC/2012; GenBank:
AFV09327.1) comprises 320 amino-acid residues, corresponding
to Gln1482 – Asp1801 of pp1a, and is part of non-structural protein
3. In the interest of an easy description, we renumber Gln1482 into
Gln1 here. A gene coding for the PLprowas ampliﬁed by the polymer-
ase chain reaction (PCR) using the forward primer 50-CTAGCTAGC-
cagttaacaatcgaagtcttagtg-30 and the reverse primer 50-
CCGCTCGAGttaatcgctactgtatttttggccggg-30. The resulting PCR prod-
uct was digested with restriction enzymes NheI and XhoI for liga-
tion into pET-28a (Novagen). Cloning was designed to include an
N-terminal hexahistidine (His6) tag and a thrombin cleavage site.
The recombinant plasmid was used to transform Escherichia coli
strain Tuner (DE3) pLacI (Novagen). Transformed cells were grown
at 37 C overnight in LB medium, supplemented with kanamycin
(50 lg/mL) and chloramphenicol (34 lg/mL). The culture was used
to inoculate LBmedium the day after.When the OD600 of the culture
reached 0.6–0.8, overexpression of the PLpro gene was induced for
20 h with the addition of isopropyl-D-thiogalactoside (IPTG, ﬁnal
concentration 0.5 mM) at 20 C. Subsequently, the culture was har-
vested by centrifugation for 30 min at7300g and 4 C. Cells were
resuspended in 30 mL buffer A (20 mM Tris–HCl, 500 mM NaCl,
10 mM imidazole, pH 8.8, 10 mM b-mercaptoethanol (BME)) and
lysed by sonication on ice. The lysate was centrifuged for 1 h at
48,000g and 4 C to remove the cell debris. The supernatant
was applied to a HisTrap™ nickel column (GE Healthcare) and the
His-tagged protein was eluted with buffer B (20 mM Tris–HCl,
500 mM NaCl, 500 mM imidazole, pH 8.8, 10 mM BME) using stan-
dard protocols. The target protein was processed overnight by
thrombin (Sigma) cleavage at 4 C to remove the His-tag. Left with
six extra residues (GSHMAS) at the N-terminus after this processing
step, the PLpro was further puriﬁed by gel ﬁltration (HiLoad™ 16/60
Superdex 200 column, GE Healthcare) using buffer C (20 mM Tris–
HCl, 150 mM NaCl, pH 8.8, 10 mM BME).
2.2. Crystallization and diffraction-data collection
Puriﬁed PLpro was concentrated to 11 mg/ml in buffer C.
Crystallization was performed at 18 C by using a Phoenixcrystallization robot (Art Robbins) employing the sitting-drop
vapor-diffusion method, with mixing 0.25 ll of protein and
0.25 ll of reservoir to equilibrate against 75 ll reservoir solution.
The following commercially available screens were used: SaltRx™,
PEG/Ion™ 1 & 2 Screen, Index™, and PEG Rx™ 1 & 2 (Hampton
Research). Crystals were observed under condition 19 of Index™.
Optimized crystals were subsequently obtained within one day
using 0.056 M NaH2PO4, 1.344 M K2HPO4, pH 8.0, and 15% glycerol
as reservoir, with mixing 2 ll of protein and 2.5 ll of reservoir to
equilibrate against 500 ll reservoir solution.
Crystals were ﬂash-cooled in a 100-K nitrogen-gas stream. A
dataset to 2.50 Å resolution was collected using synchrotron radi-
ation at wavelength 0.98 Å at beamline P11 of DESY, Hamburg. Dif-
fraction data were processed with the program XDS (Kabsch, 2010).
The space group was determined as C2, with unit-cell parameters
a = 100.89 Å, b = 47.67 Å, c = 88.43 Å, b = 122.35. Diffraction data
statistics are given in Table 1.2.3. Phase determination, model building and reﬁnement
The structure of the MERS-CoV PLpro was solved by molecular
replacement using the program BALBES (Long et al., 2008). The pro-
gram selected molecule A of the SARS-CoV PLpro (PDB: 2FE8, Ratia
et al., 2006) as the most suitable search model. The resulting model
for the MERS-CoV PLpro was inspected and rebuilt using Coot
(Emsley et al., 2010), and reﬁned using autoBUSTER (Bricogne
et al., 2011). The ﬁnal reﬁnement statistics are presented in Table 1.
Atomic coordinates and structure factors have been deposited in
the PDB with accession code 4P16. All ﬁgures except Fig. 3 and
74 J. Lei et al. / Antiviral Research 109 (2014) 72–82Supplementary Fig. 1 have been prepared using Pymol (Schröding-
er; http://www.pymol.org/).2.4. Site-directed mutagenesis
Using the pET28a-PLpro plasmid as template, site-directedmuta-
genesis (L106W mutation) was performed by PCR with the follow-
ing primers (mutated codons shown in bold and underlined):
gtacgttctctcaaatggagtgataataat and acaattattatcactccatttgagagaacg.
The PCR products were digested by DpnI (Thermo Scientiﬁc) and
transformed to DH5a directly. The positive clones were incubated
in LB medium overnight and the bacterial culture was harvested
next day. The plasmids were puriﬁed from the bacteria using the
GeneJET PlasmidMiniprepKit (ThermoScientiﬁc). All DNAplasmids
were sequenced and the correctness of the mutation was veriﬁed.
The procedures for the expression of the construct carrying the
L106W mutation and the puriﬁcation of the corresponding protein
were the same as described above for the wild-type protein.Fig. 1. Structure of the MERS-CoV papain-like protease (PLpro). (A) Cartoon view of
the enzyme’s overall structure. a-Helices (cyan) and b-strands (purple) are
numbered, polypeptide segments devoid of repetitive secondary structure, includ-
ing loops and turns, are brown. The ubiquitin-like (Ubl) domain is encircled by a red
dashed line. The catalytic domain consists of the thumb, ﬁngers, and palm
subdomains. The structural zinc ion in the ﬁngers domain is indicated by a gray
sphere. The Ca atoms of the catalytic-site cysteine (111), histidine (278), and
aspartate (293) residues are also shown (yellow, blue, and red sphere, respectively).
The red arrow indicates the substrate-binding region and points to the catalytic site.
(B) The four cysteine ligands (Cys191, Cys194, C226 and C228) and the structural
zinc ion (gray sphere) in the zinc ribbon of the ﬁngers domain. An Fo-Fc omit density
(green; contoured at 5 r above the mean) for the zinc is shown. Sulfur atoms are
shown in yellow, oxygen in red, nitrogen in blue, and carbon in light blue. The
coordinative bonds between the sulfur atoms and the zinc ion are indicated by
dashed red lines. (C) The catalytic triad: Cys111, His278, and Asp293. Atom colors:
carbon, yellow; oxygen, red; nitrogen, blue. A 2Fo-Fc electron density (gray;
contoured at 1.0 r above the mean) is also displayed. CME111: Cys111 covalently
modiﬁed by b-mercaptoethanol.2.5. Assays of MERS-CoV PLpro in vitro activity
Before usage of the freshly prepared MERS-CoV PLpro for deter-
mination of the enzyme kinetics, the number of free (non-oxi-
dized) cysteine residues was determined by titration with
Ellman’s reagent (Riddles et al., 1983). All procedures followed
the standard protocol of the Ellman’s Reagent kit (Thermo Scien-
tiﬁc). The resulting number of 13.4 ± 0.3 free cysteine residues
(out of 13 in the amino-acid sequence) showed that in the bulk
of our enzyme preparation, the catalytic Cys111 was in the free
state and fully reduced.
We also examined the inﬂuence of ethylene diamine tetraacetic
acid (EDTA) on the enzyme’s activity, but found no effect of con-
centrations up to 10 mM. However, at a concentration of 20 mM,
a decrease of enzymatic activity was observed, presumably due
to the removal of Zn2+ from the PLpro zinc ﬁnger. Accordingly, the
kinetic assays were carried out in the absence of EDTA.
All enzymatic assays were performed in 20 mM Tris–HCl,
150 mM NaCl, pH 7.9, 2 mM dithiothreitol (DTT), using a 96-well
microtiter plate. Three ﬂuorogenic substrates, Cbz-Arg-Leu-Arg-
Gly-Gly-7-amino-4-methylcoumarin (Z-RLRGG-AMC) (Bachem),
Z-LRGG-AMC and ubiquitin-AMC (Ub-AMC) (BostonBiochem),
were used. The enzymatic cleavage reactions were monitored at
25 C by measuring the increased ﬂuorescence (kex: 360 nm; kem:
460 nm) resulting from AMC release, using an Flx800 ﬂuorescence
spectrophotometer (BioTek). Reactions were started by addition of
the substrate to the microtiter plate. The kinetic assays were run
under the following conditions: 1 lM MERS-CoV PLpro with differ-
ent concentrations (10–100 lM) of Z-RLRGG-AMC in a ﬁnal vol-
ume of 100 ll, 1 lM MERS-CoV PLpro with different
concentrations (20–160 lM) of Z-LRGG-AMC in a ﬁnal volume of
100 ll, or 100 nM PLpro with different concentrations (0.2–
1.2 lM) of Ub-AMC in a ﬁnal volume of 50 ll. In case of the PLpro
carrying the L106W mutation, the following conditions were used:
125 nM enzyme with different concentrations (10–100 lM) of Z-
RLRGG-AMC in a ﬁnal volume of 100 ll, 250nM enzyme with dif-
ferent concentrations (10–100 lM) of Z-LRGG-AMC in a ﬁnal vol-
ume of 100 ll, or 125 nM PLpro with different concentrations
(0.1–1.0 lM) of Ub-AMC in a ﬁnal volume of 50 ll. Initial velocities
were determined from the linear section of the curve. Since no sat-
uration could be observed, the data were ﬁtted to the equation v/
[E]tot. = kapp[S], where kapp approximates kcat/KM, as described in
Barretto et al. (2005) and Wojdyla et al. (2010). A calibration curve
was generated by measuring the ﬂuorescence of free AMC in reac-
tion buffer at concentrations ranging from 0.005 lM to 2.5 lM.3. Results and discussion
3.1. Overall structure of MERS-CoV PLpro
The MERS-CoV PLpro molecule is divided into two parts, the N-
terminal ubiquitin-like (Ubl) domain and the catalytic domain
(Fig. 1A). The Ubl domain consists of the 62 N-terminal amino-acid
residues. It comprises ﬁve b-strands, one a-helix, and one 310-helix
(g) in the order b1-b2-a1-b3-b4-g1-b5. The catalytic domain
forms an extended right-hand scaffold, which comprises three dis-
tinct subdomains: thumb, ﬁngers, and palm. The thumb domain
consists of six a-helices and four b-strands with the order a2-
a3-b6-b7-a4-b8-a5-a6-a7-b9. The ﬁngers domain contains b10–
b13, the N-terminal 16 residues (Glu231–Leu246) of b14, g2, a8,
and the C-terminal 7 residues (Phe312–Ser318) of b19. It also
includes a zinc ﬁnger, in which four cysteine residues (Cys191,
Cys194, Cys226, and Cys228) coordinate a zinc ion (Fig. 1A and
B). The palm domain comprises six b-strands: b15–b18, the C-ter-
minal 10 residues (Ser247–Thr256) of b14, and the N-terminal 10
residues (Asp302–Leu311) of b19. In the loop Gly271-Gly277
between b15 and b16, residues Ile272–Ala275 are not deﬁned by
electron density, indicative of high ﬂexibility. The substrate-bind-
ing site is a solvent-exposed region between the palm and thumb
Fig. 2. Comparison of the MERS-CoV PLpro with other coronavirus PLpros and human
ubiquitin-speciﬁc protease 14 (USP14). (A) Superposition of the MERS-CoV PLpro Ubl
domain (green) with the SARS-CoV PLpro Ubl domain (purple, PDB: 2FE8, chain A,
Ratia et al., 2006) and yeast DSK2 (yellow, PDB: 2BWF, chain B, Lowe et al., 2006).
All three adopt the globular b-grasp fold. The N and C termini of the MERS-CoV PLpro
Ubl domain are marked. (B) Superposition of the catalytic domain (CD) of MERS-
CoV PLpro (green) with the SARS-CoV PLpro CD (red, PDB: 2FE8, chain A, Ratia et al.,
2006) and with TGEV PL1pro (blue, PDB: 3MP2, Wojdyla et al., 2010). Four regions of
structural differences are apparent (encircled by dashed black lines and labeled
with roman numbers). The structural zinc ion in the ﬁngers domain of each
protease is indicated by a green, red, and blue sphere, respectively. (C) Side-by-side
comparison of USP14 (left, purple, PDB: 2AYN, chain B, Hu et al., 2005) and MERS-
CoV PLpro CD (right, green). The Ca positions (yellow, blue, and red sphere,
respectively) of the catalytic-triad cysteine, histidine, and aspartate residues are
shown for each protease. The two ‘‘blocking loops’’, BL1 and BL2, of USP14 are
highlighted in cyan. The loop b14-b15 (salmon) of MERS-CoV, which corresponds to
BL1 of USP14, is oriented towards the opposite direction in the PLpro. The dashed red
line indicates the loop b15-b16 in MERS-CoV PLpro (corresponding to BL2 of USP14)
that was not deﬁned by electron density in our structure. The dashed black lines
indicate disordered regions in USP14. The structural zinc ion of MERS-CoV PLpro is
indicated by a gray sphere. The black arrow indicates the substrate binding region
of each protease. The N and C termini of each enzyme are marked with letters in
italics.
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triad consisting of Cys111, His278, and Asp293 is located (Fig. 1C).
Interestingly, the segment 283-RLKGG;Li-289, located in the
connection between the active-site residues His278 and Asp293,
constitutes a potential autocleavage site for the MERS-CoV PLpro.
Whereas we have some preliminary evidence for partial autopro-
cessing of our protease preparation at this site (data not shown),
the electron density maps suggest that no cleavage has occurred
in the crystallized protein at this position. Residues 283–285 are
at the C-terminus of strand b16 and the two glycines are the cen-
tral residues of a b-turn that leads into strand b17, which starts
with Leu288. Thus, the residues concerned are part of well-deﬁned
secondary-structure elements and therefore, although largely
accessible to solvent, cannot be accommodated by the substrate-
binding site of the protease. However, whether or not in-trans PLpro
autocleavage occurs at this position in the viral polyprotein,
remains to be investigated.
3.2. Comparisons of the overall fold
3.2.1. The Ubl domain
As the Ubl domain and the catalytic domain of the MERS-CoV
PLpro are two independent domains, we treated them separately
in searching the Protein Data Bank (PDB) for structural similarity
using the DALI server (Holm and Rosenström, 2010). However,
we note that there are no variations in the relative orientation of
these domains with respect to each other, as the Ubl domain is
anchored to the core domain by two strong salt-bridges in MERS-
CoV PLpro (Arg16...Glu64, 2.9 Å; Asp39 . . .His81, 3.5 Å) as well as
in SARS-CoV PLpro (the TGEV PL1pro lacks the Ubl domain). The
structural comparisons show that the MERS-CoV Ubl domain is
similar to other proteins or domains featuring the ubiquitin fold
(Table 2, Fig. 2A). The Ubl domain of SARS-CoV PLpro is essential
for downregulating IRF3 or the NF-jB antiviral signaling pathway,
but the Ubl domain alone is not sufﬁcient to do so (Frieman et al.,
2009). On the other hand, the Ubl domain is often involved in pro-
tein–protein interactions (Mueller and Feigon, 2003; Su and Lau,
2009; Hartmann-Petersen and Gordon, 2004) and it is conceivable
that the Ubl domain of MERS-CoV PLpro could interfere with host
signaling-pathway proteins by providing a binding scaffold, which
is necessary for the catalytic domain to accomplish its function of
antagonizing the host’s innate immune response.
3.2.2. The catalytic domain: comparison with other coronaviral PLpros
The catalytic domain of the MERS-CoV PLpro is more similar
to that of the SARS-CoV (Ratia et al., 2006) than to the PL1pro ofTable 2
Structural comparisons of MERS-CoV PLpro with other proteins.
MERS-CoV PLpro ubiquitin-like (Ubl) domain
PDB/chain ID Z score RMSD
SARS-CoV PLpro Ubl 2FE8/A 11.0 1.1
DSK2 2BWF/B 5.5 2.1
hHR23A 1P98/A 5.2 2.1
MERS-CoV PLpro catalytic domain (CD)
PDB/chain ID Z score RMSD
SARS-CoV PLpro CD 2FE8/A 27.4 2.4
TGEV PL1pro 3MP2/A 18.7 3.1
USP14 2AYN/B 13.0 3.1
USP21 3I3T/A 12.8 3.0
USP2 2HD5/A 12.8 3.1
USP7 1NB8/B 10.5 3.5
1 Aligned Ca atoms/total Ca atoms.
2 Sequence identity.Transmissible Gastroenteritis Virus (TGEV; Wojdyla et al., 2010)
(Table 2). There are four regions of signiﬁcant structural difference
between the coronaviral PLpros (Fig. 2B). The ﬁrst (Region I) concerns
the two helices a2 and a3 in the N-terminal region of the thumb
domain of the MERS-CoV and SARS-CoV enzymes, which are absent
in the TGEV PL1pro (Figs. 2B and 3). The second region (II in Fig. 2B) of(Å) Ca1 % id2 References
61/64 28 Ratia et al. (2006)
54/77 17 Lowe et al. (2006)
56/78 7 Mueller and Feigon (2003)
(Å) Ca1 % id2 References
246/251 32 Ratia et al. (2006)
198/211 23 Wojdyla et al. (2010)
199/337 14 Hu et al. (2005)
196/303 15 Ernst et al. (2013)
198/315 15 Renatus et al. (2006)
198/333 15 Hu et al. (2002)
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gers domain. Two b-hairpins, which provide the cysteine residues
for binding the structural zinc ion in this region, are twisted todiffer-
entdegrees among the three structures. The third structurallydiffer-
ent area (III in Fig. 2B) is the connecting region between the ﬁngers
and palm domains. In the MERS-CoV PLpro, the C-terminal 10 resi-
dues of b14 extend into the palm domain and an 8-residue loop
(Thr257–Val264) connects b14 and b15. In the SARS-CoV enzyme,
the corresponding strand is divided into two separate b-strands,
b12 and b13, the latter of which is mostly part of the palm domain,
and a shorter loop formed by 5 residues (Gln256 - Leu260) connects
b13andb14. In the TGEVPL1pro, there are two loops (Ser157–Thr160
andVal166–Val170) andone310-helix (Pro161–Phe165) connecting
the ﬁngers and palm domains. The different connections in the var-
ious PLpros might lead to different mutual orientations of the two
domains, which in turn might affect the enzymatic activities of the
individual PLpros. Finally, Region IV (Fig. 2B) concerns the loop
between b15 and b16 (Gly271–Gly277), four residues of which are
not deﬁned by electron density inMERS-CoV PLpro. The correspond-
ing region in TGEV PL1pro (Gly177–Gly182) and in SARS-CoV PLpro
(Gly267–Gly272) is shorter by one residue compared to the MERS-
CoV enzyme; it forms a loop between b8 and b9 in TGEV PL1pro
and a short 310-helix between b14 and b15 in the SARS-CoV enzyme.
However, this region is veryﬂexible andadoptsdifferentpositions in
the three copies of the SARS-CoV PLpro in the asymmetric unit of the
crystal (Ratia et al., 2006). In the recently reported crystal structure
of the SARS-CoV PLpro (C112S mutant) in complex with ubiquitin
(Chouet al., 2014), theb14-b15 loop shows large conformational dif-
ferences compared to its position in the free enzyme. The two gly-
cines framing this loop are absolutely conserved among the
coronavirus PLpros, but the residues between them are different in
each of the enzymes, suggesting that there must be differences in
the interaction between the loop and the substrates.Fig. 3. Structure-based alignment of MERS-CoV PLpro (GenBank: AFV09327.1), SARS-CoV
structure elements of MERS-CoV PLpro (top) and SARS-CoV PLpro (bottom) are indicate
residues coordinating the zinc ion are marked by black inverted triangles. The mobile b
Residues that are identical in the three CoV proteases are marked by white letters in red
outline. The ﬁgure was created by using the program ESPript (Gouet et al., 1999).3.2.3. Comparison with cellular ubiquitin-speciﬁc proteases
Even though the catalytic domain of the MERS-CoV PLpro only
shares 12–15% sequence identity with the cellular ubiquitin-spe-
ciﬁc proteases (USPs), it features largely the same fold as the USPs
with known three-dimensional structures (Table 2). A side-by-side
comparison of the catalytic domain of the MERS-CoV PLpro with
USP14 is shown in Fig. 2C. The most signiﬁcant differences are
located in the connecting region between the ﬁngers and palm
domains. The two ‘‘blocking loops’’, BL1 and BL2, of USP14 regulate
the deubiquitinating activity (Hu et al., 2005) (Fig. 2C). BL1 of
USP14 connects the ﬁngers and palm domains. It is a 22-residue
loop between b8 and b9, exposed to the substrate-binding surface.
The corresponding loop in MERS-CoV PLpro is much shorter (8 res-
idues) and connects b14 and b15. Furthermore, this short loop does
not face the substrate-binding region but rather points to the bot-
tom of the thumb domain of MERS-CoV PLpro (Fig. 2C), and can thus
not be considered a ‘‘blocking loop’’. As a consequence, the sub-
strate-binding site (indicated by the black arrow in Fig. 2C) is larger
in MERS-CoV PLpro than in the USPs, probably enabling the enzyme
to not only bind ubiquitin but also viral polyprotein. Connecting
b10 and b11, the other blocking loop, BL2 (residues Gly427–
Gly433), of USP14 is near the active site and undergoes conforma-
tional change upon substrate binding (Hu et al., 2005); this loop
corresponds to b15-b16 (residues Gly271–Gly277) of MERS-CoV
PLpro which unfortunately lacks electron density for four of its
seven residues (see above).
3.3. The active site of MERS-CoV PLpro
The MERS-CoV PLpro possesses a catalytic triad consisting of
Cys111, His278, and Asp293 (Figs. 1C and 4A). Cys111 in the
MERS-CoV PLpro is situated at the N-terminus of a4 and points into
the substrate-binding cleft between the palm and thumb domains.PLpro (GenBank: AY278741.1), and TGEV PL1pro (GenBank: AJ271965.2). Secondary-
d. Residues of the catalytic triad are marked by black asterisks. The four cysteine
15–b 16 loop (corresponding to BL2 of USP14) is indicated by a dashed purple box.
boxes with blue outline, while similar residues are marked by red letters and a blue
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has been modiﬁed by disulﬁde bond formation with b-mercap-Fig. 4. Active site of MERS-CoV PLpro. (A) Superposition (stereo view) of catalytic-triad r
PDB: 2FE8, chain A, Ratia et al., 2006), and USP14 (thin orange sticks, PDB: 2AYN, chain
MERS-CoV PLpro is indicated. CME111: Cys111 covalently modiﬁed by b-mercaptoethano
cysteine in MERS-CoV PLpro (106-LSDNN(CME)-111, green, shown as thick sticks, with bo
purple labels). (C) Stereo view of the same b-turn, Ser107-Asp108-Asn109-Asn110, in ME
r above the mean). The main chain of the b-turn and of the (modiﬁed) catalytic residue C
and Trp93 (side-chain) are displayed as well. Hydrogen bonds are indicated by dashed re
(green) and 142-NGSC-145 in SARS-CoV Mpro (gray, PDB: 2BX3, Tan et al., 2005). Residu
main-chain atoms between this pair of four residues is 0.62 Å. The two black arrow
proteolytic reaction.toethanol (BME) during crystallization of the enzyme. His278 is
located at the N-terminus of b16; its Nd1 atom is 4.4 Å from theesidues of MERS-CoV PLpro (thick green sticks), SARS-CoV PLpro (thin purple sticks,
B, Hu et al., 2005). The distance between Nd1 of His278 and the sulfur of Cys111 in
l. (B) Superposition (stereo view) of the polypeptide segment preceding the catalytic
ld green labels) and SARS-CoV PLpro (107-WADNNC-112, purple, thin sticks, smaller
RS-CoV PLpro, with the corresponding 2Fo-Fc electron density (blue; contoured at 1.5
ME111 is shown in pink, while side-chains are green. Gly161, Lys105 (main chain),
d lines. (D) Stereo view of a superposition of 108-DNN(CME)-111 in MERS-CoV PLpro
es of MERS-CoV PLpro and SARS-CoV Mpro (in brackets) are labeled. The RMSD of all
s point to the presumable position of the oxyanion in the transition state of the
78 J. Lei et al. / Antiviral Research 109 (2014) 72–82sulfur of Cys111. This large distance is likely due to the BME-mod-
iﬁcation of Cys111; in most papain-like protease structures, the
distances are between 3.7 Å and 4.0 Å (Fig. 4A). Although the
side-chain of His278 is somewhat displaced from its regular posi-
tion in the catalytic triad, Asp293 and Cys111 align well with their
counterparts in SARS-CoV PLpro and USP14 (Fig. 4A).
The transition state of the proteolytic reaction catalyzed by
papain-like cysteine proteases is stabilized in the oxyanion hole,
through two hydrogen bonds usually donated by the main-chain
amide of the catalytic cysteine residue and by the side-chain amide
of a glutamine or asparagine residue ﬁve or six positions N-termi-
nal to the catalytic cysteine. For example, the latter residue is Asn
in USP14 and HAUSP (Hu et al., 2002, 2005), and Gln in the ubiqui-
tin C-terminal hydrolases (UCH)-L3 and UCH-L1 (Johnston et al.,
1997). In TGEV PL1pro, there is also a glutamine residue (Gln27)
at this position (Wojdyla et al., 2010). In SARS-CoV PLpro, the corre-
sponding residue is Trp107, the indole NH of which has been pro-
posed to stabilize the oxyanion transition state (Fig. 4B).
Accordingly, replacing Trp by Ala abrogates the protease activity
(Ratia et al., 2006). Surprisingly, the corresponding residue in the
MERS-CoV PLpro is Leu106, the side-chain of which is incapable
of hydrogen bonding (Fig. 4B).
How then is the oxyanion transition state stabilized in MERS-
CoV PLpro? Ratia et al. (2006) have discussed Asn110 as a potential
additional component of the oxyanion hole in the SARS-CoV PLpro.
This residue is highly conserved amongst the coronaviral PLpros,
including the MERS-CoV enzyme (Asn109) and in TGEV PL1pro
(Asn30). In all three coronavirus PLpros of known three-dimen-
sional structure as well as in USP14, this Asn residue occupies posi-
tion i+2 of a b-turn (Ser107-Asp108-Asn109-Asn110 in MERS-CoV)
that precedes the catalytic cysteine in the polypeptide chain. How-
ever, the side-chain of Asn109 is oriented away from the oxyanion
hole and is involved in a strong (2.9 Å) hydrogen-bond with the
carbonyl oxygen of conserved Gly161 of the thumb subdomain
(Fig. 4C); therefore, it is unlikely to undergo a conformational
change that will bring it into the neighborhood of the catalytic cen-
ter. The other two potential hydrogen-bonding donors in this b -
turn, Ser107 and Asn110, are heavily engaged in hydrogen bonds
across the turn (Fig. 4C) and therefore equally unlikely to undergo
the conformational changes necessary to reorient their side-chains
towards the catalytic center.
So if none of the side-chains in this b -turn is a likely compo-
nent of the oxyanion hole, what about main-chain amides? We
notice that the segment between residues 108 (position i+1 of
the b-turn) and 111 can be superimposed (with an RMSD of
0.62 Å for main-chain atoms) onto the loop (142-NGSC-145)
preceding the catalytic nucleophile, Cys145, in SARS-CoV main
protease (Mpro; PDB: 2BX3, Tan et al., 2005) (Fig. 4D). The Mpro
is a cysteine protease comprising a chymotrypsin-like fold; in
these enzymes, the oxyanion hole is formed by the main-chain
amides of the catalytic cysteine (or serine) and of the penultimate
residue (Taranto et al., 2008; Wu et al., 2013). The penultimate
residue before the catalytic nucleophile in chymotrypsin-like pro-
teases is absolutely conserved as a glycine, whereas in MERS-CoV
PLpro, the conserved Asn109 resides at this position. However,
this asparagine is in a left-handed (aL) conformation, with posi-
tive / and w angles (56 and 34, resp.) in the Ramachandran
plot, just like the conserved glycine in the catalytically competent
conformation of chymotrypsin-like proteases (Verschueren et al.,
2008; Tan et al., 2005). In fact, Asn and Asp are the only residues
apart from Gly, for which this conformation is observed at a sig-
niﬁcant rate in protein structures (Hutchinson and Thornton,
1994). (Incidentally, in MERS-CoV PLpro, the i+1 residue of this
b-turn, Asp108, is also in an aL conformation, so that we have
the rare situation here of a b-turn with both i+1 and i+2 residues
having positive //w angles). In spite of the Asn109 main-chain Natom being relatively well superimposable onto the correspond-
ing atom of Gly143 in SARS-CoV Mpro, we note that the N-H vec-
tor of this amide does not point towards the position that would
likely be assumed by the oxyanion. Whether or not the necessary
(minor) rearrangement may occur, remains to be answered by
elucidating the structure of a complex between the MERS-CoV
PLpro and a transition-state analogue.
In any case, our mutation experiment described below clearly
demonstrates that the oxyanion hole of the MERS-CoV PLpro is
deﬁcient.3.4. The substrate-binding site of MERS-CoV PLpro
In the MERS-CoV polyproteins, the three cleavage sites for the
PLpro are KLIGG;DV (Nsp1-2), RLKGG;AP (Nsp2-3), and KIVGG;AP
(Nsp3-4). The P1 and P2 positions are strictly conserved as glycine
residues. P5 is Lys or Arg and P4 Leu or Ile, whereas P3 can be Ile,
Lys, or Val. In the SARS-CoV polyprotein, cleavage by the PLpro also
occurs behind LXGG, but X is either Asn or Lys (Barretto et al.,
2005), never a hydrophobic residue such as Ile or Val as in
MERS-CoV. The LXGG motif is also present at the C-terminus of
ubiquitin. In addition to the crystal structure of the complex
between the C112S mutant of SARS-CoV PLpro and ubiquitin
(Chou et al., 2014), the structure of the wild-type SARS-CoV PLpro
with Ubal has very recently been reported (Ratia et al., 2014; Ubal
is ubiquitin with the C-terminal carboxylate reduced to an alde-
hyde, which forms a covalent bond with the catalytic Cys residue).
However, as the PDB coordinates for the latter structure have not
been released yet, we rely for our further discussion on the struc-
tures of the ubiquitin complex of the SARS-CoV PLpro (C112S
mutant) and on the structure of USP14-Ubal; Hu et al., 2005).
The structural homology between these two enzymes and MERS-
CoV PLpro allowed us to deduce conclusions concerning the sub-
strate-binding site of the latter. When we superimposed the sub-
strate-binding sites of MERS-CoV PLpro, SARS-CoV PLpro(C112S),
and USP14, we found a remarkable degree of structural conserva-
tion but also some important differences (Fig. 5).
In MERS-CoV PLpro, the substrate-binding site is lined by resi-
dues Leu106–Tyr112 and Gly161–Arg168 of the thumb subdo-
main, and Phe269–Tyr279, Pro250, and Thr308 of the palm
subdomain (Fig. 5C and D). Asn109, Cys111, the NH of Tyr112,
Gly277, and His278 (all conserved in SARS-CoV PLpro and USP14)
form the spatially restricted S1 site (Fig. 5C and D), which can only
accommodate glycine as the P1 residue. Pro163 (Leu163 in SARS-
CoV PLpro, Gln196 in USP14), Asp164 (main chain), Gly277 (con-
served), and Tyr279 (side-chain, conserved) are involved in shap-
ing the equally restricted S2 subsite, which again is speciﬁc for
glycine (Fig. 5C and D). Replacement of Tyr274 in SARS-CoV PLpro
(corresponding to Tyr279 of the MERS-CoV enzyme) by Ala leads
to a loss of protease activity (Barretto et al., 2005).
The S3 subsite of MERS-CoV PLpro features important differ-
ences from the one in the SARS-CoV enzyme. In the SARS-CoV
PLpro(C112S)-Ub and SARS-CoV PLpro-Ubal complexes (Chou et al.,
2014; Ratia et al., 2014), the main-chain amide of P3-Arg (substrate
residues are indicated in italics in what follows) forms an H-bond
with the side-chain OH of Tyr265 (Fig. 5A and S1A). In MERS-CoV
PLpro, this residue is replaced by Phe269 (Fig. 5C and D). Replace-
ment of Tyr265 by Phe in SARS-CoV PLpro reduces the peptidolytic
activity of the enzyme by a factor of 2.4 and its deubiquitinating
activity by 57% (Chou et al., 2014). Another potentially important
difference between the S3 subsites of SARS-CoV PLpro and MERS-
CoV PLpro is that Glu162 of the former is replaced by Ala162 in
the latter (Fig. 5A and C), reducing the negative electrostatic poten-
tial of this region in the MERS-CoV PLpro (Fig. 5E and F). This might
enable the MERS-CoV enzyme to accommodate hydrophobic P3
Fig. 5. Substrate-binding site of MERS-CoV PLpro as deduced from the homologous structures of SARS-CoV PLpro and USP14. (A) The substrate-binding site in SARS-CoV PLpro
(purple, PDB: 4M0W (complex with ubiquitin), Chou et al., 2014). The ﬁve C-terminal residues of ubiquitin, RLRGG, are displayed as cyan sticks. Ubiquitin residues are labeled
by cyan letters in italics, and residues of SARS-CoV PLpro involved in binding the C-terminal residues of ubiquitin are labeled with black regular letters. The salt-bridge
Glu168 . . .Arg42 and the hydrogen bond Tyr265 . . .Arg74 are highlighted in insets. (B) The substrate-binding site of USP14 (red, PDB: 2AYO, complex with ubiquitin-aldehyde,
Hu et al., 2005). The ﬁve C-terminal residues of ubiquitin, RLRGG-aldehyde, in the complex are displayed as blue sticks (GLZ, amino-acetaldehyde, i.e. the aldehyde of the C-
terminal G76). The P1-P5 residues of ubiquitin are labeled by blue letters in italics. Residues of USP14 involved in binding the C-terminal residues of ubiquitin are labeled with
regular black letters. The covalent bond between sulfur (Cys113) and carbon (GLZ76) is displayed by a green line. The salt-bridge Glu201 . . .Arg72 is highlighted in the inset.
(C) The substrate-binding site of MERS-CoV PLpro. Residues that are different from those of SARS-CoV PLpro and USP14 are underlined. The supposed positions of the subsites
S1–S5 are indicated. (D) Structure-based alignment of residues involved in deﬁning speciﬁcity subsites in MERS-CoV PLpro, SARS-CoV PLpro, and USP14. Conserved residues are
in red. Arg168 of MERS-CoV PLpro (corresponding to Glu168 and Glu201 in SARS-CoV PLpro and USP14, respectively) is in blue. Phe269 of the MERS-CoV enzyme (Tyr265 in
SARS-CoV PLpro) is green. Residues involved in shaping subsites are labeled by the symbol for the corresponding subsite (S1–S5) above the alignment. Residues contributing to
S1, S2, and S4, but not S3 and S5, are conserved. (E, F) Electrostatic surfaces of the substrate-binding regions of SARS-CoV PLpro (E) and MERS-CoV PLpro (F), colored according
to electrostatic potential (blue, positive potential; red, negative potential). The electrostatic surfaces were calculated using the APBS plugin in PyMOL (Baker et al., 2001). The
contouring level is -8 kBT/e to 8 kBT/e. Orientation is the same as in the cartoon representations in (A and C). The S3 and S5 subsites are indicated by orange labels. (E) Glu162
and Glu168 of SARS-CoV PLpro are marked. (F) Ala162 and R168 of MERS-CoV PLpro are marked.
Table 3
Kinetic parameters of MERS-CoV PLpro.
Z-RLRGG-AMC Z-LRGG-AMC Ub-AMC
MERS-CoV PLpro
WT# 1.31 ± 0.14* 1.00 ± 0.01 (5.06 ± 0.35)  102
L106W 53.27 ± 5.10 60.16 ± 7.00 (1.70 ± 0.58)  103
SARS-CoV PLpro
WT (Lindner et al., 2005) 3.6 7.86  102
WT (Barretto et al., 2005) 4.48  103
# Wild-type.
* kapp (min1 mM1).
J. Lei et al. / Antiviral Research 109 (2014) 72–82 79residues such as Ile or Val, as they occur at the PLpro cleavage sites
of the MERS-CoV (but not the SARS-CoV) polyprotein.
The S4 subsite in MERS-CoV PLpro is a hydrophobic pocket
formed by Thr308, Pro250, Phe269, and the Cb atom of conserved
Asp165. The side-chain carboxylate of the latter may interact with
the amide of P4-Leu. Accordingly, replacement of this aspartate by
Ala in SARS-CoV PLpro inactivates the enzyme (Chou et al., 2014).
Phe269 is involved in both the S3 subsite (see above) and in mak-
ing hydrophobic interactions with the P4-Leu of polyprotein cleav-
age sites or ubiquitin. In addition, the mobile b 15–b 16 loop
probably contributes to the S4 site (as deduced from the structure
of SARS-CoV PLpro in complex with ubiquitin (Chou et al., 2014)),
but we are unable to provide a detailed description because of
missing electron density (see above). In any case, however, the
loop of the MERS-CoV enzyme is devoid of a large aromatic residuethat could make interactions with Leu73 (P4) (and Leu71 (P6)) of
ubiquitin, as observed for Tyr269 of SARS-CoV PLpro (Chou et al.,
2014).
80 J. Lei et al. / Antiviral Research 109 (2014) 72–82The S5 subsite of MERS-CoV PLpro is also different from that in
USP14 and in the SARS-CoV PLpro. The side-chain of the P5-Arg
forms a salt-bridge with Glu201 in the USP14-Ubal complex (Hu
et al., 2005; Fig. 5B and S1B) and the same is observed for
Glu168 of SARS-CoV PLpro with Ubal (Ratia et al., 2014). However,
in the SARS-CoV PLpro(C112S) complex with ubiquitin (Chou
et al., 2014), this same glutamate residue interacts with an arginine
of the core of ubiquitin (Arg42) instead of the P5-Arg (Fig. 5A). This
may be due to the position of Glu168 and hence the entire S5 site
of the PLpro at the surface of the protease, near the entrance to the
substrate-binding cleft. While not forming a pocket, the S5 is still
important for substrate binding, because the Glu168 side-chain is
at the core of a region with pronounced negative electrostatic
potential (see Fig. 5E). Interestingly, this important glutamate of
USP14 and SARS-CoV PLpro is replaced by Arg168 in MERS-CoV
PLpro (Fig. 5D), changing the electrostatic potential of the S5 site
of the latter to more positive and therefore less ideal for interacting
with the P5-Arg or Arg42 of ubiquitin, or the P5 Lys/Arg of the
MERS-CoV polyprotein cleavage sites (Fig. 5F). Indeed, Chou et al.
(2014) have replaced Glu168 of SARS-CoV PLpro by Arg and found
a 25-fold decrease in deubiquitinating activity of the enzyme.
Mesecar and colleagues have demonstrated that the SARS-CoV
PLpro is a druggable target. They used their crystal structure of
the enzyme (Ratia et al., 2006) in a virtual screening campaign
and reported crystal structures of the complex with the optimized
hit compound, GRL0617 (5-amino-2-methyl-N-[(1R)-1-naphtha-
len-1-ylethyl]benzamide) and derivatives thereof (Ratia et al.,
2008; Baez-Santos et al., 2014). Interestingly, the inhibitors do
not bind to the catalytic center directly but near the S3 and S4 sub-
sites as well as the mobile b 14–b 15 loop (b 15–b 16 in MERS-CoV
PLpro) (Ratia et al., 2008; Baez-Santos et al., 2014). As there are
important differences in the S3 subsite as well as in the mobile
loop between the SARS-CoV and the MERS-CoV PLpros, it is unlikely
that these compounds will inhibit the PLpro and the replication of
MERS-CoV. However, virtual or real screening approaches might
be expected to result in the discovery of different small-molecule
compounds binding to a similar site in MERS-CoV PLpro.
3.5. In-vitro peptide-hydrolysis and deubiquitinating activities of wild-
type MERS-CoV PLpro and its L106W variant
We tested the PLpro-catalyzed hydrolysis of the peptides Z-
RLRGG-7-amino-4-methylcoumarin (AMC) and Z-LRGG-AMC as
mimics of the cleavage sites in the viral polyproteins. For this assay
(and the one described below), only freshly prepared enzyme was
used, in which the catalytic cysteine residue was shown to be in a
free, reduced (and hence active) state by titration with Ellman’s
reagent and by the absence of an effect of adding EDTA up to a con-
centration of 10 mM (see Materials & Methods). We found that the
peptides were hydrolyzed by MERS-CoV PLpro in vitro, and that the
initial rate of hydrolysis increased with raising the substrate con-
centration. However, we were unable to observe saturation of
the reactions. This might indicate a large Km value and/or low
enzyme efﬁciency. We used the pseudo-ﬁrst-order rate constant,
kapp, to estimate an approximate kcat/Km value. The kapp rates were
1.31 ± 0.14 min1 mM1 for Z-RLRGG-AMC and 1.00 ± 0.01 min1 -
mM1 for Z-LRGG-AMC, values signiﬁcantly lower than those
reported for the SARS-CoV PLpro (Table 3). This may be explained
by the apparent deﬁciency of the oxyanion hole of the MERS-CoV
PLpro and the inability of the side-chain of Phe269 to form the
hydrogen bond with the main-chain amide of P3-Arg observed
for the corresponding Tyr265 in SARS-CoV PLpro (Chou et al.,
2014). In order to examine whether this relatively low activity is
caused by the deﬁciency of the oxyanion hole, i.e. the lack of a
side-chain available for oxyanion stabilization through hydrogen
bonding, we prepared the L106W mutant of the MERS-CoV PLproand found its peptide-hydrolyzing activities on Z-RLRGG-AMC
and Z-LRGG-AMC, respectively, to be 40-fold and 60-fold higher
than those of the wild-type enzyme (Table 3). This is a clear dem-
onstration of the deﬁciency of the oxyanion hole in the MERS-CoV
PLpro and shows that the contribution to oxyanion stabilization by
the main-chain amide of residue 109, if at all existent, is far less
efﬁcient than by a tryptophan residue in position 106, as found
in the SARS-CoV PLpro.
We also tested the deubiquitinating activity of the MERS-CoV
PLpro in vitro using Ub-AMC as a substrate. We determined kapp
as (5.06 ± 0.35) x 102 min1 mM1. This value is also lower than
the rate constants reported for SARS-CoV PLpro by different
research groups (Table 3). Again, the less-than-perfect oxyanion
hole and the replacement of Tyr265 of SARS-CoV PLpro by Phe269
in MERS-CoV PLpro may be responsible for this. In addition, the
replacement of Glu168 of SARS-CoV PLpro by Arg168 in the
MERS-CoV enzyme very likely weakens the interaction with ubiq-
uitin. The deubiquitinating activity of the MERS-CoV PLpro carrying
the L106W mutation was found to be 3.4-fold higher than that of
the wild-type enzyme (Table 3). Our results demonstrate that the
MERS-CoV PLpro displays both peptidase and deubiquitinase activ-
ities in vitro and is thus suitable for screening chemical libraries for
inhibitors.
4. Conclusions
The crystal structure of the MERS-CoV PLpro provides critical
information on this important potential drug target. The unique
architecture of the oxyanion hole, which differs from all papain-
like proteases that have been structurally characterized so far,
may be of fundamental interest. Because of unique features of its
S3 and S5 subsites as well as in the ﬂexible loop (b 15–b 16) cov-
ering the substrate-binding site, we expect that the MERS-CoV
PLpro will show differences in ubiquitin recognition, compared to
SARS-CoV PLpro and USP14. Both peptidase and deubiquitinating
activities of MERS-CoV PLpro have been demonstrated in vitro.
Introduction of the L106W mutation leads to a restoration of the
oxyanion hole of the PLpro and an enhancement of both catalytic
activities. Furthermore, the structural differences from homolo-
gous host enzymes such as USP14 should allow the design of antiv-
irals devoid of too many side effects.
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